Regis Technologies Chromatography Catalog

Significance of the Topic

Chiral and achiral chromatographic techniques, along with complementary derivatization and bioluminescent reagents, are essential tools in pharmaceutical development, environmental analysis, and bioanalytical research. They enable precise resolution of enantiomers, rapid separations, direct analysis of complex matrices, and sensitive detection of biological targets.

Study Overview

This white paper presents an integrated portfolio of chromatographic stationary phases, ion-pair and derivatization reagents, bioluminescent substrates, and custom manufacturing services from Regis Technologies. It highlights product chemistries, performance benchmarks, and application examples across chiral HPLC/SFC, achiral SFC, reversed-phase HPLC, IAM chromatography, GC derivatization, and bioluminescent assays.

Methodologies and Instrumentation

• Chiral HPLC/SFC: Whelk-O 1 Pirkle phases, Reflect polysaccharide coated/immobilized phases, ChiroSil crown-ether columns.
• Achiral SFC: Celeris ethyl-pyridine, amino, PEI and arginine phases for fast, green separations.
• Reversed-Phase HPLC: Evoke™ C18 columns, Restricted Access Media (RAM) and Semi-Permeable Surface (SPS) phases for serum direct injection.
• Immobilized Artificial Membrane (IAM) chromatography: IAM.PC.DD2 and IAM Fast-Screen Mini columns for phospholipophilicity and permeability prediction.
• Ion-Pair HPLC: S-Series sulfonates and Q-Series quaternary amines to improve retention and peak shape of ionic analytes.
• GC Derivatization: Silylation (BSTFA, BSA, MSTFA, MtBSTFA), acylation (HFBA, PFPA, TFAA), alkylation reagents and chiral derivatizing agents.
• Bioluminescent Assays: High-purity D-luciferin and coelenterazine substrates for ATP, luciferase and in vivo imaging.

All methods are supported by high-precision instruments under GMP manufacturing and strict quality control.

Main Results and Discussion

Extensive application data demonstrate high resolution (Rs > 1.5), long column lifetimes under harsh conditions, scalability from analytical to preparative formats, reproducible rapid screening workflows, and superior correlation of IAM retention to biological permeability and distribution metrics.

Practical Applications and Benefits

• Comprehensive chiral screening in three days via free sample service.
• Scalable SFC and HPLC methods to minimize solvent use and cycle times.
• Direct biological matrix injection reduces sample prep and biohazard waste.
• Robust ion-pair methods for co-analysis of neutral and charged species.
• GC derivatization reagents for enhanced volatility, selectivity, and detector response.
• Bioluminescent substrates for high-sensitivity in vitro and in vivo assays.

Future Trends and Opportunities

Anticipated developments include expanded UHPLC/UHPSFC phase chemistries, AI-assisted method selection, microfluidic IAM formats for ultra-high throughput, sustainable sorbent materials, integration of proteomic and metabolomic assays, and novel bio-mimetic stationary phases.

Conclusion

Regis Technologies provides an end-to-end solution for modern analytical challenges—from chiral and achiral separations to bioassay substrates and custom API manufacturing. Their broad product range, GMP-certified production, and expert support accelerate development timelines and ensure reproducible high-quality results.

References

• Pidgeon C.; Ong S.; Bungay P.; Immermann F.; Wallace D.; IAM Chromatography: An in vitro Screen for Predicting Drug Membrane Permeability; J. Med. Chem. 1995, 38, 590–594.
• Ong S.; Lang M.; Thermodynamics of Solute Partitioning into Immobilized Artificial Membranes; Anal. Chem. 1995, 67, 755–762.